全基因组CRISPR筛选发现MAD2L1BP和ANAPC15是CD30+外周T细胞淋巴瘤中布伦妥昔单抗韦多汀敏感性的靶点

IF 12.8 1区医学 Q1 HEMATOLOGY

Leukemia Pub Date : 2024-10-21 DOI:10.1038/s41375-024-02441-1

Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takanori Teshima, Yibin Yang, Masao Nakagawa

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

查看原文本刊更多论文

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues